Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 240.98 -2.12 (0.87%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $243.10 | 52 Week High | $333.65 | |||
| Open | $242.02 | 52 Week Low | $223.02 | |||
| Day High | $243.32 | P/E | 30.86 | |||
| Day Low | $240.13 | EPS | $7.81 | |||
| Volume | 812,898 | |||||
